Ramdev’s “Coronil” Claim to Cure Coronavirus Proves False; It is Immunity Booster


Patanjali Ayurved’s Swasari Coronil Kit claimed to cure coronavirus in a very controversial launch. To which, the government last week stopped Patanjali from advertising the medicines as a virus cure and had asked for details of clinical trials that Ramdev claimed were "100 percent" successful.


The coronil kit was then investigated by the medical experts and concluded that the kit is not a cure for coronavirus, it is just meant for the immunity and therefore, News agency Press Trust of India said the Ayush ministry has confirmed that Patanjali can sell the product but not as a cure for COVID-19.  "AYUSH Ministry has only given permission to sell this particular formulation as an immunity booster, not as a medicinal cure for COVID-19," the ministry said, according to PTI.


According to news agency ANI, Ramdev said in the press conference, "Ayush Ministry said Patanjali has done appropriate work for COVID management. It said Patanjali has started working in the right direction. We have procured a license for these medicines from the state department which is connected with Ayush Ministry. The treatment word is not used. These medicines have no metallic items.”He added, "We have no disagreement with Ayush Ministry. There is no restriction on Coronil, Swashhari, Giloy, Tulsi, and Ashwagandha. I thank the Ayush Ministry and the Narendra Modi government.”


Patanjali had earlier launched the coronil kit which claimed that with its proper clinical trials, "In three days, 69 percent, 100 percent patients tested negative in 7 days. We submitted data to the Ayush Ministry. We have submitted research of our clinical trials to Ayush Ministry.” However, now the ministry has said that coronil can be sold but not as a cure drug for coronavirus but as an immunity booster.




Read More Latest Bollywood Movie Reviews & News

Read More Sports News, Cricket News

Read More Wonderful Articles on Life, Health and more

Read More Latest Mobile, Laptop News & Review

Leave a Reply